The European Commission has approved BridgeBio's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market clash with Pfizer. The oral drug ...

This publication has not been sponsored or paid for by any external entities. The insights and perspectives shared are organic, reflecting the author's genuine viewpoints and professional expertise ...

A. A mark is a given and known sign by which a thing can be distinguished from all others of its kind. Thus a trademark is used to distinguish the article bearing it from all imitations of the same ...